AstraZeneca has been granted FDA approval for its once-weekly diabetes medicine Bydureon (exenatide) to treat children (aged 10-18) with type-2 diabetes. The drug, an injectable suspension, aims to lower blood sugar rates. The approval is based on a late-stage study which indicated that Bydureon drastically decreased blood glucose levels in adults compared to the placebo used. Already approved in the US for adults with type-2 diabetes, Bydureon can now be used to extend that treatment to children. Elaborating on this, AstraZeneca senior executive Mene Pangalos stated that, “This decision is an important milestone for the care of this younger patient population by providing a convenient, once-weekly treatment option.”
Read more here.